Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
A post-marketing study in participants with early Alzheimer's disease treated with lecanemab is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles. [NA]
A University of Seville-sponsored clinical trial is investigating whether moderate wine consumption affects healthy aging via postprandial e…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Implementation of AIP Services for Older Adults With AD
Northwestern University is implementing AIP services for older adults with Alzheimer's disease and mild cognitive impairment, and the trial …
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy [EARLY_Phase 1]
Early-phase 1 clinical trial update evaluating the safety and feasibility of using Exablate to disrupt the blood-brain barrier in individual…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Digital Interventions in Neuro-Rehabilitation: Gotcha! [NA]
Completed clinical trial evaluating digital interventions in neuro-rehabilitation. Results were posted on 2026-01-22.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: UPenn Observational Research Repository on Neurodegenerative Disease
The University of Pennsylvania is conducting an observational research repository for neurodegenerative diseases and is currently recruiting…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Neurocognitive Assessment Platform 4 Alzheimer
This clinical trial update notes that a neurocognitive assessment platform for Alzheimer disease and mild cognitive impairment is currently …
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Collaborative Care Coordination Program for Alzheimer's Disease and Related Dementias [NA]
A completed clinical trial evaluating a collaborative care coordination program for Alzheimer's disease and related dementias; the update pr…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: ALSENLITE: Senolytics for Alzheimer's Disease [Phase 1, Phase 2]
ALSENLITE, a senolytic being studied for Alzheimer's disease and Mild Cognitive Impairment, is currently in Phase 1/Phase 2 trials with stat…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease [NA]
This clinical trial update summarizes a completed study evaluating ExAblate blood-brain barrier opening as a treatment approach for Alzheime…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Cognitive Health in Ageing Register: Investigational and Observational Trial Studies in Dementia Research (CHARIOT): Prospective Readiness Cohort (PRO) Longitudinal Study
A prospective readiness cohort study (CHARIOT PRO) in dementia research led by Imperial College London, focusing on Alzheimer's disease; the…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD) [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating deep repetitive transcranial magnetic stimulation of the precuneus for Alzheimer's disease and is c…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Amyloid Beta-peptide 1-40 and Alzheimer's Disease [NA]
A clinical trial investigating Amyloid Beta-peptide 1-40 for Alzheimer's disease has completed.
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) [Phase 3]
A Phase 3 trial of donanemab (LY3002813) in participants with preclinical Alzheimer’s disease is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Erythrocyte Complement Receptor 1 and Alzheimer Disease [NA]
A completed clinical trial assessing erythrocyte complement receptor 1 in Alzheimer's disease. The study (NCT01565434) sponsored by CHU de R…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease [NA]
A completed clinical trial evaluating ultrasound-guided stellate ganglion block as a treatment for Alzheimer's disease and cognitive impairm…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction [NA]
This clinical trial update describes a recruiting study investigating the miR-342-5p/AnkG pathway in early synaptic dysfunction related to A…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK
A Hong Kong–based prospective observational study to explore early detection approaches for Alzheimer's disease across individuals with Alzh…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Comprehensive Assessment of Neurodegeneration and Dementia
Clinical trial at McGill University is actively recruiting to comprehensively assess neurodegeneration and dementia across multiple cognitiv…
-
EMA approval · 2026-01-16EMA Authorised: Tauvid (Flortaucipir (18F)) — Eli Lilly Nederland B.V.
The EMA authorized Tauvid, a radiopharmaceutical PET imaging agent (flortaucipir F18) developed by Eli Lilly Nederland B.V. The product is i…
-
EMA approval · 2026-01-16EMA Authorised: Amyvid (florbetapir (18F)) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised Amyvid (florbetapir (18F)) for radionuclide imaging. The marketing authorization holder is Eli Lill…
-
FDA approval · 2026-01-16FDA Approved: LEQEMBI — Supplemental Application (Eisai Inc.)
The FDA approved a supplemental application for LEQEMBI (lecanemab) from Eisai Inc., related to its labeling/indication.
-
EMA approval · 2026-01-16EMA Authorised: Rivastigmine Hexal (rivastigmine) — Hexal AG
Hexal AG's rivastigmine product has been authorized in the EU for dementia-related indications including Alzheimer's disease and Parkinson's…
-
EMA approval · 2026-01-16EMA Authorised: Rivastigmine Sandoz (rivastigmine) — Sandoz GmbH
The European Medicines Agency authorised Rivastigmine Sandoz (rivastigmine) for dementia indications, including Alzheimer's disease and Park…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: Study to Understand Novel Biomarkers in Researching Dementia
A Washington University study is recruiting to understand novel biomarkers in dementia. The study will include participants with Alzheimer's…